Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by J. Rao
Total Records ( 2 ) for J. Rao
  M.E. Boroujeni , P. Gowda , J. Johnson , J. Rao and S. Saremy
  Bone marrow derived-Human Mesenchymal stem cells (hMSCs) are non-hematopoetic, stromal cells that demonstrate multilineage differentiation capacity and being capable to give rise to diverse tissues, including bone and cartilage. Due to this capability, hMSCs are currently evaluated for regenerative medicine, repopulating injured tissues and clinically ablated diseased tissues with healthy, terminally differentiated cells. Thus, for therapeutic applications, enough numbers of homogenous MSCs are required. In this study, the population doubling of bone marrow derived hMSCs was assessed in early and late passages. It was noted that in healthy cells, generally, the population doubling increases over time due to the slower rate of cell growth. Subsequently, the mesengenic multipotency of BM-MSCs for chondrogenesis, osteogenesis and adipogenesis was investigated in early and late doublings. According to our findings, the early passage hMSCs treated with the differentiation agents exhibited approximately 100, 48±10.33 and 28.6±6.62% osteocytes, chondrocytes and adipocytes, respectively. Whereas, the late passage hMSCs subjected to the differentiation agents only demonstrated the high degree of osteogenicity but they revealed neither chondrogenicity nor adipogenicity. Furthermore, the Expression of Oct4, Sox2 and Nanog genes in undifferentiated human BM-derived MSCs was studied. The result revealed the Oct4 is expressed at very low levels in early passage MSCs and disappeared at late passage however Nanog and Sox2 were almost undetected in MSCs. In conclusion, the proliferation rates and other properties of the cells gradually change during expansion and therefore, it is recommended to not expand hMSCs beyond four or five passages.
  P Jin , X. j Lu , J. q Sheng , L Fu , X. m Meng , X Wang , T. p Shi , S. r Li and J. Rao

Estrogen is reported to have a protective effect on colon cancer; however, the underlying mechanism is unclear. Impaired mismatch repair plays an important role in colonic carcinogenesis. The purpose of this study was to investigate the association of estrogen on regulating mismatch repair expression in colonic epithelial cells. In cultured COLO205 cells, the effect of estradiol (E2) and antagonist ICI182.780 on the expression of hMLH1 and hMSH2 was studied using reverse transcription-PCR and Western blotting. The correlation between serum level E2 and the expression of hMLH1 and hMSH2 in colonic mucosal tissue of 42 healthy individuals was also examined using reverse transcription-PCR and immunohistochemical staining. E2 increased the expression of hMLH1 in COLO205 cells, which was suppressed by ICI182.780. However, the effect of E2 on hMSH2 expression was not significant in COLO205 cells. In healthy individuals, a strong positive correlation of E2 level with hMLH1 expression in normal colonic epithelial cell was observed when serum E2 level was >45 pg/mL, but no correlation was seen between E2 and hMSH2 expression. E2 affects the expression of hMLH1 but not hMSH2 in vitro, and high serum E2 level correlates with hMLH1 expression in vivo. These findings suggest that the anticolonic cancer effect of estrogen may be related to hMLH1 regulation. Cancer Prev Res; 3(8); 910–6. ©2010 AACR.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility